RxDoctor Payments Data

Jo Ann Fields, MD

Internal Medicine · Salisbury, MDNPI 1386612844

Payments from drug & device makers

$553in general payments, 2019–2025

Across 27 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$269
  • Pfizer$77
  • Exact Sciences$49
  • Lilly USA, LLC$44
  • Dexcom, Inc.$42
  • GSK$36
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$553100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$553 in reported general payments places this provider in the 65th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$110,601
Medicare patients
447
Services billed
1,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide132$154,294
EliquisApixaban86$104,265
JardianceEmpagliflozin61$76,127
TrulicityDulaglutide33$59,197
FarxigaDapagliflozin Propanediol29$41,971
XareltoRivaroxaban13$18,821
MounjaroTirzepatide14$18,417
JanuviaSitagliptin Phosphate13$17,633
TradjentaLinagliptin18$17,607
EntrestoSacubitril/Valsartan15$16,577
Breo ElliptaFluticasone/Vilanterol21$15,176
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,883
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$11,873
MyrbetriqMirabegron13$11,620
Arnuity ElliptaFluticasone Furoate34$10,243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$269$154,294132 claims
PfizerEliquis, Premarin$77$110,34899 claims
Lilly USA, LLCTrulicity, Mounjaro$44$77,61347 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$36$61,64894 claims
AstraZenecaFarxiga, Symbicort$16$47,41245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →